利拉鲁肽治疗非酒精性脂肪肝疗效的Meta分析

发布时间：2018-05-26 05:13

本文选题：肝疾病 + 脂肪肝　；参考：《重庆医学》2017年15期

【摘要】：目的系统评价利拉鲁肽治疗非酒精性脂肪肝病(NAFLD)的疗效。方法计算机检索Pubmed、EMBASE、the Cochrane library、中国知网、万方数据库和中文科技期刊数据库,收集利拉鲁肽治疗NAFLD的随机临床对照研究(RCT),按排除和纳入标准筛选文献后,将纳入文献进行质量评价并提取相应的数据后采用RevMan5.3软件进行Meta分析。结果共纳入7个RCT共计500例非酒精性脂肪性肝病患者。使用利拉鲁肽12~48周后,可显著改善非酒精性脂肪性肝病患者的组织学特征,并降低患者血清中的丙氨酸氨基转移酶水平[加权均数差(WMD)=-25.32,95%CI(-37.22,-13.41),P0.01]和天冬氨酸氨基转移酶水平[WMD=-24.56,95%CI(-35.10,-14.03),P0.01]。但并不能降低患者的血清中三酰甘油水平[WMD=-14.38,95%CI(-48.95,-20.20),P=0.42]和总胆固醇水平[WMD=-15.55,95%CI(-36.20,-5.10),P=0.14]。结论利拉鲁肽对NAFLD有一定的治疗作用。
[Abstract]:Objective to evaluate the therapeutic effect of Lilaru peptide in the treatment of non-alcoholic fatty liver disease (NAF LDD). Methods A computerized search was conducted for Pubmedan EMBASEN the Cochrane library.China knowledge Network, Wanfang Database and Chinese Science and Technology Journal Database were used to collect the randomized clinical controlled study on the treatment of NAFLD with liraluP, and the literature was screened according to the exclusion and inclusion criteria. The quality of literature was evaluated and the corresponding data were extracted. Meta analysis was carried out with RevMan5.3 software. Results A total of 500 patients with non-alcoholic fatty liver disease were included in 7 RCT. After 48 weeks of treatment, the histopathological characteristics of patients with non-alcoholic fatty liver disease were significantly improved and the serum levels of alanine aminotransferase (alt) in patients with non-alcoholic fatty liver disease were significantly improved [WMD-25.32C95CI-37.22U -13.41 P0.01] and aspartate aminotransferase levels (WMD-24.56-95CI-35.10- 14.03P0.01). But it did not decrease the serum triacylglycerol level [WMD-14.38 / 95] and the total cholesterol level [WMD-15.595 / CI-36.20 / -5.10 / P0.14]. Conclusion Lilaru peptide has a certain therapeutic effect on NAFLD.
【作者单位】：四川大学华西医院临床药学部;四川大学临床药学与药物不良反应研究室;四川大学华西医院老年科;四川大学分子医学中心/生物治疗国家重点实验室;
【分类号】：R575.5

【相似文献】